4ONG

Fab fragment of 3D6 in complex with amyloid beta 1-40

4ONG の概要

• エントリーDOI: 10.2210/pdb4ong/pdb
• 関連するPDBエントリー: 4ONF
• 分子名称: 3D6 FAB ANTIBODY HEAVY CHAIN, 3D6 FAB ANTIBODY LIGHT CHAIN, Amyloid beta A4 protein, ... (7 entities in total)
• 機能のキーワード: antibody, amyloid beta peptide, immune system
• 由来する生物種: Mus musculus (mouse); 詳細
• 細胞内の位置: Membrane; Single-pass type I membrane protein: P05067
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 54789.84

構造登録者

Feinberg, H.,Saldanha, J.W.,Diep, L.,Goel, A.,Widom, A.,Veldman, G.M.,Weis, W.I.,Schenk, D.,Basi, G.S. (登録日: 2014-01-28, 公開日: 2014-06-11, 最終更新日: 2024-11-27)

主引用文献

Feinberg, H.,Saldanha, J.W.,Diep, L.,Goel, A.,Widom, A.,Veldman, G.M.,Weis, W.I.,Schenk, D.,Basi, G.S.
Crystal structure reveals conservation of amyloid-beta conformation recognized by 3D6 following humanization to bapineuzumab.
Alzheimers Res Ther, 6:31-31, 2014

PubMed Abstract: Immunotherapy targeting amyloid-β peptide is under active clinical investigation for treatment of Alzheimer's disease (AD). Among the hypotheses being investigated for impact on clinical outcome are the preferred epitope or conformation of amyloid-β to target for treatment, and the mechanism of action underlying immunotherapy. Bapineuzumab (humanized 3D6), a neo-epitope specific antibody recognizing amyloid-β1-5 with strong preference for an exposed Asp residue at the N-terminus of the peptide, has undergone advanced clinical testing for treatment of AD.

PubMed: 25024748
DOI: 10.1186/alzrt261

実験手法

X-RAY DIFFRACTION (2.2 Å)